Regeneron Pharmaceuticals Inc. (REGN) has reported progress in its efforts to develop what it describes as a "multi-antibody cocktail that can be administered as prophylaxis before exposure to the SARS-CoV-2 virus or as a treatment for those already infected." In addition, Regeneron said antibodies from humans who have recovered from Covid-19 "have been isolated to maximize the pool of potentially potent antibodies."
More from Stocks
I have no false illusion about striking it rich in this name, but a staple such as this can have a place in my portfolio.
In the short term, market direction is going to be dictated by reaction to extremely poor economic news.
I could be surprised but right now the charts of OMC are just not positioned for a sustained recovery rally.
With so many charts of companies in weak positions lately, it's refreshing to see charts so strong as AMD.